Environmental, Social and Governance Report

The report presents Sino Biopharmaceutical's 2024 ESG governance and performance across climate, environment, employees, product responsibility and community investment. It applied a double materiality assessment and reported total GHG emissions of 208,220.01 tCO2e, alongside a carbon-neutrality roadmap and an ahead-of-schedule 20% intensity-reduction target. The workforce totaled 24,287 employees, while board oversight and ESG governance were clearly defined. The report's ESG information was independently verified by TÜV SÜD under limited assurance.